Dana-Farber Cancer Institute Boston - #1 Cancer Center in USA & New England | CancerCareE

Dana-Farber Cancer Institute Boston

#1 Cancer Center in USA & New England • Harvard Medical School • Global Pioneer in Cellular Therapy

US News 2025: #1 Cancer NCI Comprehensive All FDA CAR-T TIL Therapy Leader

Institute Overview

Dana-Farber Cancer Institute, affiliated with Harvard Medical School and part of Dana-Farber/Brigham and Women’s Cancer Center, is ranked #1 for cancer in the United States and New England (U.S. News & World Report 2025). It is one of the world’s most innovative cancer centers, leading in cellular immunotherapy, precision medicine, and early-phase clinical trials.

#1
Cancer USA & New England
1,100+
Physicians & Scientists
500K+
Patient Visits / Year
180+
Countries Served

Global Leadership in Cellular Immunotherapy

CAR-T & TIL Therapy

  • All 6 FDA-approved CAR-T products available
  • One of the first centers worldwide to offer commercial TIL therapy (Amtagvi)
  • Leading site for next-gen CAR-T, bispecifics, and allogeneic platforms

Pediatric Oncology

  • Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
  • #1 pediatric cancer program in New England
  • World leader in pediatric CAR-T and rare tumors

Research & Trials

  • Over 700 active clinical trials
  • Home of the first cancer vaccine trials
  • Largest phase I program in New England

Cost Comparison – Dana-Farber vs Global Centers (2025)

TreatmentDana-Farber USACleveland ClinicAsan KoreaBumrungradCAMS China
CAR-T Therapy$450K–$550K$450K–$550K$300K–$400KNot available$45K–$70K
TIL Therapy (Amtagvi)$515,000$515,000Not availableNot availableTrials only
Phase I Trial AccessTop 3 USATop 10 USAModerateLimitedGrowing

Available Advanced Treatments

TreatmentAvailability
All 6 FDA CAR-T ProductsAvailable
FDA-Approved TIL Therapy (Amtagvi)Leading Center
Bispecific AntibodiesAvailable
Phase I/II Clinical TrialsTop 3 in USA
Precision Oncology & Liquid BiopsyWorld Leader
Pediatric CAR-T & Rare Tumors#1 in New England

Frequently Asked Questions

Can international patients receive CAR-T or TIL at Dana-Farber?
Yes. The International Patient Center handles all cases, including cellular therapies, with full visa and concierge support.
How fast can treatment start?
Second opinion: 3–7 days. CAR-T/TIL infusion: 4–10 weeks after approval. Expedited pathways available.
Do you accept international insurance?
Yes – direct billing with most global carriers (Allianz, Cigna Global, Bupa, AXA, Gulf insurers).

Contact & Location

Main Campus

450 Brookline Avenue
Boston, MA 02215
United States

International Patients

Phone: +1-617-632-3000
International Office: +1-617-632-5456
Email: international@dfci.harvard.edu

Ready for Treatment at the #1 Cancer Center in America?

Get access to the world’s most advanced immunotherapy, TIL therapy, and phase I trials at Dana-Farber.

Request Free Consultation

Leave a Reply

Your email address will not be published. Required fields are marked *